News Sentiment

PROK sentiment intelligence

ProKidney Corp. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 50 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.62 Week of 17 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

81/100 classification confidence.

Company focus 41

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-8.0% over one week, -11.5% over four weeks, trend inactive, and below fair value.

Latest direct headline Negative

ProKidney (NASDAQ:PROK) Trading Down 0.7% - Time to Sell?

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 81/100 classification
One-week reaction -8.0% Price reacting lower
Trend fit Trend inactive -11.5% over four weeks
Fair value -32.4% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 8
Neutral 35
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 41
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 13
Market source 12
TradingView 5
dars.gov.et 3
simplywall.st 3
MarketBeat 2
TradingKey 2
Sahm 2

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 17
Balance sheet 2
Regulatory and legal 1
Macro sensitivity 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-50 of 50
Sahm Direct company coverage

3 Promising Penny Stocks With Market Caps Up To $600M

This article identifies three promising penny stocks—ProKidney (PROK), ProQR Therapeutics (PRQR), and Rocket Pharmaceuticals (RCKT)—with market caps up to $600M, highlighting their financial health and growth potential. Despite being pre-revenue or unprofitable, these biotechnolo

Tone
Positive 61/100
Event
Market update
Published
07 May 2026 18:09
Source
Sahm
Stock Titan Direct company coverage

[SCHEDULE 13D/A] PROKIDNEY CORP. Amended Major Shareholder Report

Control Empresarial and the Slim family have amended their Schedule 13D/A filing for ProKidney Corp., disclosing a beneficial ownership of 73,842,723 shares of Class A common stock, representing 36.0% of the outstanding shares. This increase in holdings is primarily due to an exc

Tone
Neutral 50/100
Event
Market update
Published
01 May 2026 02:38
Source
Stock Titan
Stock Titan Direct company coverage

Control Empresarial converts 63.1M PROK (NASDAQ: PROK) Paired Interests into Class A shares

Control Empresarial de Capitales S.A. de C.V., a major shareholder of PROKIDNEY CORP. (NASDAQ: PROK), converted 63.1 million Paired Interests into an equal number of Class A Common Shares. This non-cash, one-for-one exchange simplified their economic stake, reducing their Class B

Tone
Neutral 50/100
Event
Deals and strategy
Published
30 Apr 2026 20:38
Source
Stock Titan
Stock Titan Direct company coverage

Executive pay, governance on agenda at ProKidney (NASDAQ: PROK) vote

ProKidney Corp. (NASDAQ: PROK) will hold its 2026 annual stockholder meeting on May 28, 2026, where shareholders will vote on the re-election of three Class I directors and the ratification of Ernst & Young LLP as the independent registered public accounting firm. The DEF 14A pro

Tone
Neutral 50/100
Event
Market update
Published
17 Apr 2026 20:09
Source
Stock Titan
Sahm Direct company coverage

April 2026 Penny Stock Highlights

This article highlights three penny stocks—ProKidney (PROK), ProQR Therapeutics (PRQR), and LexinFintech Holdings (LX)—with strong financial health and promising growth potential for April 2026. It provides an overview of each company's operations, market capitalization, and rece

Tone
Positive 65/100
Event
Market update
Published
04 Apr 2026 16:39
Source
Sahm
Stock Titan Direct company coverage

ProKidney hires ex-Shield CEO Greg Madison for rilparencel launch prep

ProKidney (Nasdaq: PROK) has appointed Greg Madison as Chief Commercial Officer, effective March 25, 2026, to lead the commercial strategy for rilparencel as it moves towards potential commercialization. Madison brings over two decades of biopharma experience, including CEO roles

Tone
Negative 40/100
Event
Market update
Published
29 Mar 2026 19:09
Source
Stock Titan
The Globe and Mail Direct company coverage

ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

ProKidney Corp. has appointed Greg Madison as its Chief Commercial Officer to lead the company's commercial strategy for rilparencel, a potential first-in-class cell therapy for chronic kidney disease (CKD) patients with diabetes. Madison brings over two decades of experience in

Tone
Positive 72/100
Event
Market update
Published
26 Mar 2026 05:39
Source
The Globe and Mail